PATENT CLAIM ANALYSIS

Application Number: 15902231
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "04400A"]

Abstract:
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

Claim (Index 5):
The antisense oligomer according to  claim 4 , or a pharmaceutically acceptable salt or hydrate thereof, wherein the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 88.0
- Lexical Diversity: 1.27586
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15122435', '15759267', '15314535', '14368307', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8441832882306479
- 35 USC 102 Novelty (BERT): 0.5983981748833863
- Combined Prediction Score: 0.8196047768959218
- Mean Citation Score: 498.759106
- Max Citation Score: 553.2
- Similarity Product: 452.8384074211122

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test